Rigshospitalet

Oncology and Hematologic Malignancies

Clinical research includes a broad cancer portfolio spanning acute myeloid leukemia, chronic lymphocytic leukemia, myelodysplastic syndromes, neuroendocrine neoplasms, lung cancer, breast cancer, pancreatic cancer, gastroesophageal cancer, melanoma, and prostate cancer.

  • Targeted anti-cancer therapy
  • CAR T-cell therapy
  • Genomic profiling
  • PET imaging
  • Myeloid and lymphoid neoplasms

The oncology programme also covers mucositis, radiation-related xerostomia, and treatment-related complications in patients receiving intensive cancer care.

Cardiovascular and Thromboembolic Disease

Research activity spans myocardial infarction, heart failure with reduced ejection fraction, atrial fibrillation, aortic stenosis, cardiogenic shock, cardiac arrest, pulmonary embolism, and venous thromboembolism.

  • Acute coronary syndromes
  • Antithrombotic treatment
  • Valve disease
  • Pulmonary vascular disease
  • Post-resuscitation care

Additional studies address peripheral artery disease, carotid atherosclerosis, transcatheter aortic valve implantation, and postoperative cardiovascular management.

Neurology, Critical Care, and Pain

The hospital supports trials in multiple sclerosis, glioblastoma, glioma, subarachnoid hemorrhage, intracerebral hemorrhage, traumatic brain injury, coma, and other disorders of consciousness.

  • Neurocritical care
  • Consciousness recovery
  • Headache and neuralgia
  • Complex regional pain syndrome
  • Diabetic neuropathic pain

Work in this area also includes trigeminal neuralgia, persistent post-traumatic headache, radicular leg pain, and pain control after orthopaedic surgery.

Respiratory, Ear-Nose-Throat, and Ophthalmology

Studies cover cystic fibrosis, bronchiectasis, primary ciliary dyskinesia, pulmonary arterial hypertension, chronic rhinosinusitis with nasal polyposis, bronchopulmonary dysplasia, and chronic pulmonary infection.

  • Airway disease
  • Nasal polyposis
  • Glaucoma surgery
  • Ocular inflammation
  • Respiratory infection

Ophthalmic research includes primary open-angle glaucoma, ocular hypertension, atopic keratoconjunctivitis, and postoperative control of intraocular pressure.

Endocrine, Autoimmune, and Infectious Disease

Research interests include antiphospholipid syndrome, rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, Sjögren’s syndrome, VEXAS, glucocorticoid-induced adrenal insufficiency, and Klinefelter syndrome.

  • Autoimmune disease
  • Reproductive endocrinology
  • Transplant-related metabolic disorders
  • Sepsis and septic shock
  • Bacterial and fungal infection

Additional work includes infertility, postpartum depression, renal transplantation, hyperglycaemia after transplantation, and treatment of necrotizing soft-tissue infection.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on Diclofenac Potassium and Rimegepant for Treating Migraine in Patients

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark
  • Study on Hydrocortisone for Stress in Patients with Polymyalgia Rheumatica or Giant Cell Arteritis and Adrenal Insufficiency

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark
  • Study on Stopping Mepolizumab or Dupilumab in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps After 12 Months Symptom-Free

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Denmark
  • Study on Semaglutide and Low-Calorie Diet for Weight Loss in Patients with New-Onset Idiopathic Intracranial Hypertension

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark
  • Study on Diclofenac Sodium and Dexamethasone Phosphate for Patients with Uncontrolled Glaucoma After Surgery

    Not recruiting

    3 1 1 1
    Denmark
  • Study Comparing Rituximab and Ocrelizumab for Patients with Active Multiple Sclerosis

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Denmark